Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors

The Journal of Clinical Investigation
E J Goetzl, K F Austen

Abstract

The interaction of human neutrophils adherent to plastic petri dishes with the purified chemotactic factors C5a and kallikrein increased their rate of aerobic glycolysis 25-120% and the activity of their hexose monophosphate shunt (HMPS) 100-600%, reaching a plateau after 2 hr at 37 degrees C. The stimulation of either pathway required a chemotactically active stimulus since neither C5 nor prekallikrein or inactivated kallikrein could enhance metabolic activity. Marked suppression of the neutrophil chemotactic response by preincubation with a chemotactic factor to achieve deactivation, 5 x 10(-7) M diisopropyl fluorophosphate, or the neutrophil immobilizing factor (NIF) did not prevent the stimulation of HMPS activity or glycolysis by chemotactic factors. The metabolic inhibitors iodoacetate and 6-aminonicotinamide at concentrations which blocked enhancement of glycolysis or HMPS activity, respectively, partially suppressed the chemotactic response of neutrophils to the chemotactic factors. The capacity of a chemotactic factor to stimulate glucose metabolism of human neutrophils is associated with a maximal chemotactic response, but this stimulation is not alone sufficient for chemotaxis.

References

Apr 1, 1970·The Journal of Clinical Investigation·R L BaehnerM L Karnovsky
Dec 1, 1972·The Journal of Experimental Medicine·E J Goetzl, K F Austen
Dec 1, 1971·The Journal of Experimental Medicine·M S Simberkoff, P Elsbach
Jun 1, 1971·The Journal of Experimental Medicine·C F NathanJ R David
Apr 1, 1968·The Journal of Experimental Medicine·P A Ward, E L Becker
Dec 1, 1965·Arthritis and Rheumatism·S E GoldfingerJ E Seegmiller
Aug 1, 1966·The Journal of Experimental Medicine·P A Ward

❮ Previous
Next ❯

Citations

Jan 1, 1984·Springer Seminars in Immunopathology·T E Hugli
Feb 1, 1976·Agents and Actions·F RossiP Patriarca
Feb 2, 1999·Clinical Reviews in Allergy & Immunology·R W ColmanA Stadnicki
Jan 1, 1978·Journal of Immunological Methods·T W Jungi
Aug 27, 1982·Journal of Immunological Methods·G L ManderinoH Showell
May 1, 1996·Immunopharmacology·R W Colman
Nov 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·C E McCallL R DeChatelet
Sep 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·D A BassC E McCall
Dec 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·D E WexlerP P Cleary
May 1, 1978·The Journal of Cell Biology·S H Zigmond
Jun 1, 1981·The Journal of Experimental Medicine·R C WigginsP M Henson
Mar 1, 1978·International Journal of Dermatology·M V Dahl
Nov 1, 1975·Journal of Periodontal Research·J H Kraal, E B Kenney
Mar 1, 1974·The Journal of Clinical Investigation·E J GoetzlK F Austen
Nov 1, 1974·The Journal of Clinical Investigation·F H ValoneE J Goetzl
Dec 1, 1974·The Journal of Clinical Investigation·J J RinehartA F LoBuglio
Apr 1, 1976·The Journal of Clinical Investigation·R B Johnston, J E Lehmeyer
Feb 1, 1979·The Journal of Clinical Investigation·C W SmithC Hassett
Oct 1, 1979·The Journal of Clinical Investigation·M S KlempnerJ I Gallin
Jun 1, 1980·The Journal of Clinical Investigation·D A BassC E McCall
May 1, 1982·The Journal of Clinical Investigation·M SchapiraR W Colman
Nov 1, 1983·The Journal of Clinical Investigation·Y T WachtfogelR W Colman
May 1, 1988·The Journal of Clinical Investigation·Y T WachtfogelR W Colman
Nov 7, 2006·Proceedings of the National Academy of Sciences of the United States of America·Alex J FayLily Yeh Jan
Jan 15, 1981·Experientia·A V SchlegerD H Kemp
Jan 1, 1976·Immunological Communications·P M Henson
Sep 1, 1978·CRC Critical Reviews in Toxicology·M N Walters, J M Papadimitriou
Jun 13, 1975·Annals of the New York Academy of Sciences·E J Goetzl
Jan 1, 1980·Journal of the American Academy of Dermatology·M E Miller
Jul 13, 2013·Thrombosis and Haemostasis·J BjörkqvistT Renné

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.